ArticleMolecular diversity2026
Novel aminoguanidine derivatives containing alkynyl moiety: synthesis and evaluation of antibacterial and antifungal activities.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The urgent global health threat of antimicrobial resistance demands innovative therapeutic strategies. Herein, we report the design, synthesis, and biological evaluation (antibacterial and antifungal activities) of two series of alkynyl-linked aminoguanidine derivatives. A critical structure-activity relationship (SAR) was revealed: the exposure of the aminoguanidine group is paramount for activity. In vitro antibacterial and antifungal activities revealed that the imidazol-2-hydrazine series exhibited inhibition against both Gram-positive and Gram-negative bacteria, with minimum inhibitory concentration (MIC) ranging from 2 to 64 μg/mL. Among them, compound IIh exhibited a MIC of 2 μg/mL against both S. aureus CMCC 25923 and Enterococcus faecalis CMCC 29212, and also demonstrated significant antifungal activity against Candida albicans SC5314 with a MIC of 2 μg/mL. Time-kill kinetics established the rapid bactericidal nature of IIh, achieving complete eradication of E. coli and S. aureus within 1-2 h. Furthermore, IIh significantly inhibited biofilm formation and compromised bacterial membrane integrity, leading to the leakage of cytoplasmic proteins and nucleic acids. Checkerboard assays revealed a synergistic relationship between IIh and conventional antibiotics, reducing their effective MICs. As a promising candidate for combating resistant infections, IIh deserves further efficacy and safety studies.
Indexed as
Identifiers
41637017What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.